Lucentis (Ranibizumab) for Eales' Disease
Part of paid clinical trials in Portland, Oregon.
- Sponsor
- Oregon Health and Science University
- Study ID
- NCT00384449
- Phase
- PHASE2/PHASE3
- Status
- Completed
Conditions
- Eales' Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 21 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ranibizumab — DRUGConsented, enrolled subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered once a month for 3 months
Study Details
The primary objective of this protocol is to look at whether Lucentis (ranibizumab) is safe and effective when used for macular edema (retinal swelling) due to Eales' disease. The secondary objective is to see if macular edema comes back within three months after the last dose of study drug is given.
Key Dates
- First listed
- Oct 6, 2006
- Start date
- Oct 31, 2006
- Status verified
- Jun 2019
- Primary completion
- Apr 30, 2009
- Completion
- Apr 30, 2009
Study Design
- Enrollment
- 1 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Lucentis (ranibizumab)Lucentis (ranibizumab)
Primary Outcome Measure
Change in OCT Thickness. [ Time Frame: Baseline and 6 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Casey Eye Institute | Portland | Oregon | 97239 | - |
Find similar trials in Portland, OR
By research site